We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Tesamorelinis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Tesamorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 73 participants.
Based on 12 studies · 1 meta-analysis · 7 RCTs · 2,022 total participants
Confidence
HighBy outcome
Tesamorelin has an evidence score of 5/10 — moderate evidence based on 12 indexed studies, including 1 meta-analysis. A prescription growth-hormone-releasing-hormone (GHRH) analog — the drug Egrifta — FDA-approved in 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Honest appraisal: unlike most peptides sold online, this one has REAL phase-3 randomized trials, but ALL of them are in ART-treated HIV patients with excess belly fat. The off-label 'anti-aging' / bodybuilding use that drives grey-market demand is NOT what the trials studied. It is a prescription injectable, not a dietary supplement; it raises IGF-1, its benefit fully reverses when you stop, and grey-market vials are unregulated. Representative study: PMID 41545261.
The commonly studied dose of Tesamorelin is Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tesamorelin (Egrifta; stabilized GHRH(1-44) analog)
A prescription growth-hormone-releasing-hormone (GHRH) analog — the drug Egrifta — FDA-approved in 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Honest appraisal: unlike most peptides sold online, this one has REAL phase-3 randomized trials, but ALL of them are in ART-treated HIV patients with excess belly fat. The off-label 'anti-aging' / bodybuilding use that drives grey-market demand is NOT what the trials studied. It is a prescription injectable, not a dietary supplement; it raises IGF-1, its benefit fully reverses when you stop, and grey-market vials are unregulated.
An FDA-approved drug with multiple phase-3 RCTs and a meta-analysis showing real visceral- and liver-fat reduction, but all evidence is confined to HIV-associated lipodystrophy.
Tesamorelin (brand name Egrifta; development code TH9507) is a synthetic, stabilized analog of human growth-hormone-releasing hormone — specifically a GHRH(1-44) peptide with an N-terminal modification that resists enzymatic degradation and extends its half-life relative to native GHRH.
It binds the pituitary GHRH receptor to stimulate the body's own pulsatile growth-hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1). The downstream GH/IGF-1 signal preferentially drives lipolysis of visceral (intra-abdominal) fat. It is given as a 2 mg once-daily subcutaneous injection.
Critically — and unlike the research peptides it is often grouped with — tesamorelin is an FDA-approved prescription drug (approved November 2010) with a genuine phase-3 evidence base.
Two multicenter, double-blind, placebo-controlled phase-3 RCTs (pooled n=806) showed visceral adipose tissue (VAT) fell about 15-18% over 26-52 weeks versus placebo in ART-treated HIV patients with excess abdominal fat, with improved triglycerides and body-image scores and without clinically meaningful glucose worsening.
A 52-week safety-extension RCT confirmed durability of the VAT reduction during continued treatment.
The drug also reduces liver fat: a Lancet HIV RCT (n=61) in HIV-associated NAFLD found a ~37% relative reduction in hepatic fat fraction over 12 months, and a JAMA RCT (n=50) showed reductions in both visceral and liver fat; a paired-biopsy transcriptomic substudy linked treatment to a favorable fibrosis-gene signature (while also flagging hepatocellular-carcinoma-related gene changes in both directions).
The most important honesty caveats: (1) ALL of the positive RCTs are in HIV patients — there is no phase-3 evidence for the 'anti-aging,' physique, or general-population fat-loss claims that drive most grey-market demand; (2) the benefit is entirely treatment-dependent — VAT reaccumulates within months of stopping; (3) a separate GHRH/tesamorelin RCT (n=152, Arch Neurol 2012) in older adults with mild cognitive impairment and healthy controls reported a favorable cognitive effect, but a more recent phase-2 open-label trial in HIV patients with abdominal obesity (n=73, 2025) found no clear neurocognitive benefit — so the cognition story is mixed and not an approved use; (4) it is a prescription injectable that raises IGF-1, carrying a theoretical neoplasia concern (contraindicated in active malignancy) and glucose/insulin effects; and (5) buying it outside a prescription means unregulated grey-market vials of unverified identity, purity and sterility.
Overall the evidence is Moderate — solid for its narrow approved visceral-fat indication, thin-to-absent for the popular off-label uses.
Tesamorelin is a stabilized GHRH(1-44) analog that binds and activates the growth-hormone-releasing-hormone receptor on pituitary somatotrophs, stimulating the body's own GH synthesis and release. An N-terminal modification slows enzymatic breakdown, giving it a longer half-life than native GHRH while preserving physiologic, pulsatile GH secretion.
By driving endogenous GH pulses, tesamorelin raises insulin-like growth factor 1 (IGF-1). In the phase-3 trials IGF-1 rose roughly 1.5- to 2-fold (about +48-65% in dose-ranging work) and stayed within or near the physiologic range. This IGF-1 rise is the surrogate marker of pharmacologic effect.
GH preferentially mobilizes intra-abdominal (visceral) fat. In ART-treated HIV patients with excess abdominal fat, tesamorelin selectively reduced visceral adipose tissue by CT while preserving subcutaneous fat — the basis for its FDA-approved indication. The same axis reduces ectopic liver fat.
How Tesamorelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.
Can be taken without food
| Form | Type |
|---|---|
| 💊Egrifta / Egrifta SV (prescription, via a clinician) | Recommended |
Tesamorelin is an FDA-approved prescription drug for HIV-associated lipodystrophy, not a dietary supplement. It should only be obtained and used under a prescription. Related GHRH analogs sold online (e.g. CJC-1295, sermorelin) are NOT approved drugs and lack tesamorelin's phase-3 evidence — its approval does not transfer to them.
Minimum: 12 weeks
Optimal: 26 weeks
Cycling: Not required
Note: Approved HIV-lipodystrophy use is 2 mg subcutaneously once daily as directed by a prescriber; the cognition RCT dosed 1 mg before bedtime to match the nocturnal GH pulse. Not a self-optimized dietary supplement.
Dose-response data unavailable. The current published research for Tesamorelin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In ART-treated HIV patients with excess abdominal fat, visceral adipose tissue fell ~15-18% versus placebo over 26-52 weeks in two pooled phase-3 RCTs (n=806). This is the approved indication and the best-evidenced effect — but it has only been shown in this specific population, not in healthy people seeking general fat loss.
A Lancet HIV RCT (n=61) found a ~37% relative reduction in hepatic fat fraction over 12 months; a JAMA RCT (n=50) showed reductions in both visceral and liver fat. A paired-biopsy substudy linked treatment to a favorable fibrosis-gene signature. Promising but not an FDA-approved indication, and the evidence is from small trials in HIV patients.
The visceral-fat reduction is entirely treatment-dependent. In the phase-3 RCTs, VAT rapidly reaccumulated within months of switching from tesamorelin to placebo — there is no durable, drug-free benefit, so it requires ongoing daily injection to maintain effect.
A GHRH/tesamorelin RCT (n=152) in older adults with mild cognitive impairment and healthy controls reported a favorable cognitive effect (notably executive function). But a more recent phase-2 open-label trial in HIV patients with abdominal obesity (n=73) found no clear neurocognitive benefit. Cognition is not an approved use and the signal is inconsistent.
Because it raises GH, tesamorelin can transiently raise fasting glucose and insulin (GH reduces insulin sensitivity). In the HIV RCTs net glucose changes at 26-52 weeks were generally not clinically meaningful, but a transient early glucose rise was seen and IGF-1 elevation warrants monitoring — relevant for anyone with diabetes or impaired glucose tolerance.
Contraindicated in active malignancy; tesamorelin raises IGF-1, a theoretical proliferative concern. Decisions about prior-cancer history require oncology input.
Contraindicated in pregnancy; avoid in breastfeeding. GH/IGF-1 stimulation is inappropriate during pregnancy and developmental effects are unknown.
Use only under medical supervision with glucose monitoring — GH excess reduces insulin sensitivity and can raise glucose.
Off-label and outside the evidence base. The phase-3 RCTs were exclusively in ART-treated HIV patients with excess abdominal fat; benefit in other populations is unproven.
Growth hormone reduces insulin sensitivity and can raise blood glucose, so tesamorelin may blunt glucose-lowering therapy. Glucose should be monitored, especially in diabetes or impaired glucose tolerance — a transient early glucose rise was seen in the trials.
The GH/IGF-1 axis interacts with glucocorticoid metabolism; the label notes potential effects on cortisol-replacement dosing via 11β-HSD-1. Doses of concomitant cortisone/cortisol-replacement may need adjustment under medical supervision.
Tip: Rotate injection sites; the NAFLD RCT reported more localized injection-site complaints in the tesamorelin arm, none judged serious.
Tip: Typical of GH/IGF-1 stimulation; report persistent symptoms to the prescriber, who may dose-adjust or stop.
Tip: Monitor glucose/HbA1c; caution in diabetes or impaired glucose tolerance. Net changes were generally not clinically meaningful at 26-52 weeks but a transient early rise occurred.
Tip: Recognized GH-axis effects; report to prescriber.
Timing is flexible for Tesamorelin — consistent daily use matters more than the time of day. The approved HIV-lipodystrophy regimen is 2 mg subcutaneously once daily, rotated injection site, independent of meals.
Tesamorelin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reactions (erythema, pruritus, pain, irritation, swelling, bruising), arthralgia / joint pain, myalgia, peripheral edema (GH-excess type effects), increased fasting glucose / reduced insulin sensitivity. Use caution if any of these apply to you: Active malignancy — tesamorelin raises IGF-1, a theoretical proliferative/neoplasia concern; it is contraindicated in active cancer; Pregnancy — contraindicated; GH/IGF-1 stimulation is inappropriate in pregnancy; Disruption of the hypothalamic-pituitary axis (hypophysectomy, pituitary tumor/surgery/radiation, head irradiation) per the approved label.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
GH can modulate CYP-mediated metabolism; the label flags possible changes in CYP-substrate exposure. Relevant given the HIV-population context where antiretrovirals are co-administered — managed by the prescriber.
Tip: Discontinue and seek care for rash, urticaria, or systemic hypersensitivity.